|
68 Companies |
|
87 Products |
|
87 Products |
|
71 Mechanisms of Action |
|
3 Trials |
|
597 News |
|
| «12345678910111213» |
- New P1 trial: Topical Sirolimus for Plantar Keratoderma in Adults With Pachyonychia Congenita (PC) (clinicaltrials.gov) - Feb 5, 2014
P1, N=15, Recruiting, Sponsor: Stanford University
- |||| Enrollment open: A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing Regimen of Fluticasone Propionate 0.05% Cream (Twice Per Week) in Reducing the Risk of Relapse When Added to Regular Daily Moisturization Using PHYSIOGEL Lotion in Paediatric Subjects With Stabilized Atopic Dermatitis (clinicaltrials.gov) - Feb 5, 2014
P4, N=120, Recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting
- |||| Stelara (ustekinumab) / J&J
Enrollment open: A Study of Ustekinumab (STELARA (clinicaltrials.gov) - Jan 27, 2014
P2, N=72, Recruiting, Sponsor: Janssen Pharmaceutical K.K.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Dupixent (dupilumab) / Sanofi, Regeneron
Biomarker, Enrollment change: Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - Jan 22, 2014
P2, N=380, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Recruiting N=240 --> 380
- ||| Dupixent (dupilumab) / Sanofi, Regeneron
Biomarker, Enrollment closed: Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - Jan 22, 2014
P2, N=380, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
N=240 --> 380 Recruiting --> Active, not recruiting
- |||| lotamilast 0.5% ointment (DMVT-501 0.5% ointment) / Roivant
Trial completion: A Phase 2 Study of E6005 in Patients With Atopic Dermatitis (clinicaltrials.gov) - Jan 20, 2014
P2, N=78, Completed, Sponsor: Eisai Co., Ltd.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial withdrawal: Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD) (clinicaltrials.gov) - Jan 16, 2014
P1, N=0, Withdrawn, Sponsor: Sanofi Pasteur, a Sanofi Company
Active, not recruiting --> Completed Terminated --> Withdrawn
- ||| difamilast (MM36) / Otsuka, Medimetriks
Trial completion: A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis (clinicaltrials.gov) - Jan 15, 2014
P1, N=92, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Terminated --> Withdrawn Recruiting --> Completed
- |||| Trial completion: An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - Jan 13, 2014
P2, N=151, Completed, Sponsor: PreCision Dermatology, Inc.
Recruiting --> Completed Recruiting --> Completed
- MRX 6 / Akari Therap
New P1/2 trial: Double-Blind, Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2% (clinicaltrials.gov) - Jan 7, 2014
P1/2, N=0, Not yet recruiting, Sponsor: Celsus Therapeutics PLC
- Enrollment change: Investigation of Chronic Inflammatory Processes in Male Individuals With Hypohidrotic Ectodermal Dysplasia (clinicaltrials.gov) - Jan 6, 2014
P=N/A, N=38, Completed, Sponsor: University Hospital Erlangen
Recruiting --> Completed N=48 --> 38
- | Trial completion: Investigation of Chronic Inflammatory Processes in Male Individuals With Hypohidrotic Ectodermal Dysplasia (clinicaltrials.gov) - Jan 6, 2014
P=N/A, N=38, Completed, Sponsor: University Hospital Erlangen
N=48 --> 38 Recruiting --> Completed
- Preclinical: The Effect of Bathing and Moisturizers on Skin Hydration in Atopic Dermatitis: an in Vivo Study (clinicaltrials.gov) - Jan 5, 2014
P=N/A, N=22, Completed, Sponsor: Srinakharinwirot University
- |||| Xeljanz (tofacitinib) / Pfizer
Clinical: Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema) (clinicaltrials.gov) - Dec 28, 2013
P2, N=70, Recruiting, Sponsor: Pfizer
Recruiting --> Completed Not yet recruiting --> Recruiting
- Trial completion: Studies of Heritable Disorders of Connective Tissue (clinicaltrials.gov) - Dec 17, 2013
P=N/A, N=1335, Completed, Sponsor: National Institute on Aging (NIA)
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||| MEDI 4212 / AstraZeneca
Trial completion: A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL (clinicaltrials.gov) - Dec 15, 2013
P1, N=86, Completed, Sponsor: MedImmune LLC
Recruiting --> Completed Active, not recruiting --> Completed
- |||| tradipitant (VLY-686) / Vanda
Enrollment open: Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis (clinicaltrials.gov) - Dec 8, 2013
P2, N=68, Recruiting, Sponsor: Vanda Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| KHK4577 / Kyowa Kirin
New P2 trial: Phase 2 Study of KHK4577 (clinicaltrials.gov) - Dec 4, 2013
P2, N=90, Recruiting, Sponsor: Kyowa Hakko Kirin Company, Limited
- |||| timapiprant (OC000459) / Chiesi
Enrollment open: Effect of OC000459 on Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Dec 4, 2013
P2, N=200, Recruiting, Sponsor: Atopix Therapeutics, Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| tradipitant (VLY-686) / Vanda
New P2 trial: Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis (clinicaltrials.gov) - Dec 4, 2013
P2, N=68, Recruiting, Sponsor: Vanda Pharmaceuticals
- ||||| timapiprant (OC000459) / Chiesi
New P2 trial: Effect of OC000459 on Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Dec 3, 2013
P2, N=200, Recruiting, Sponsor: Atopix Therapeutics, Ltd.
- Trial completion, Preclinical: Role of Pseudogene in Incontinentia Pigmenti, and Its Potential Treatment (clinicaltrials.gov) - Dec 2, 2013
P=N/A, N=50, Completed, Sponsor: National Taiwan University Hospital
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||||| Xeljanz (tofacitinib) / Pfizer
Clinical: Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema) (clinicaltrials.gov) - Dec 2, 2013
P2, N=70, Recruiting, Sponsor: Pfizer
- |||| pegcantratinib (SNA-120) / Sienna
Enrollment open: A Study to Evaluate the Efficacy, Safety and Tolerability of CT327 in Atopic Dermatitis (clinicaltrials.gov) - Nov 28, 2013
P2, N=210, Recruiting, Sponsor: Creabilis SA
Recruiting --> Completed Not yet recruiting --> Recruiting
- Clinical: Pilot Study Evaluating the Efficiency and the Tolerance of the PDT in the Treatment of Epidermal Dysplasia for Patients Affected by Hereditary DEB (clinicaltrials.gov) - Nov 25, 2013
P=N/A, N=5, Not yet recruiting, Sponsor: Centre Hospitalier Universitaire de Nice
- Clinical: Bleach Bath Treatment of Adults With Atopic Dermatitis (clinicaltrials.gov) - Nov 25, 2013
P=N/A, N=40, Not yet recruiting, Sponsor: University of Rochester
- IO biomarker: VIDATOPIC: Impact of Vitamin D Supplementation on Severity of Pediatric Atopic Dermatitis (clinicaltrials.gov) - Nov 25, 2013
P=N/A, N=100, Not yet recruiting, Sponsor: Pontificia Universidad Catolica de Chile
- Enrollment change: Phenotypic Properties in Individuals Affected With XLHED (clinicaltrials.gov) - Nov 24, 2013
P=N/A, N=30, Completed, Sponsor: Edimer Pharmaceuticals
Not yet recruiting --> Recruiting N=150 --> 30
- | Trial completion: Phenotypic Properties in Individuals Affected With XLHED (clinicaltrials.gov) - Nov 24, 2013
P=N/A, N=30, Completed, Sponsor: Edimer Pharmaceuticals
N=150 --> 30 Recruiting --> Completed
- Trial completion: Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care (clinicaltrials.gov) - Nov 24, 2013
P=N/A, N=10, Completed, Sponsor: Stanford University
Recruiting --> Completed Recruiting --> Completed
- recombinant ectodysplasin A1 (APO200) / Onxeo, Pierre Fabre
Trial completion: A Phase 1, Open-label, Multicenter, Safety and Pharmacokinetic Study of EDI200 (clinicaltrials.gov) - Nov 24, 2013
P1, N=6, Completed, Sponsor: Edimer Pharmaceuticals
Recruiting --> Completed Recruiting --> Completed
- Trial termination: A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing (clinicaltrials.gov) - Nov 19, 2013
P3, N=1, Terminated, Sponsor: Shire Regenerative Medicine, Inc.
Recruiting --> Completed Active, not recruiting --> Terminated
- Clinical: Photocil (Topical) for the Treatment of Atopic Dermatitis (clinicaltrials.gov) - Nov 18, 2013
P=N/A, N=50, Recruiting, Sponsor: Applied Biology, Inc.
- |||| Dupixent (dupilumab) / Sanofi, Regeneron
Trial completion: Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - Nov 18, 2013
P2, N=109, Completed, Sponsor: Regeneron Pharmaceuticals
Active, not recruiting --> Terminated Active, not recruiting --> Completed
- ||| Enrollment open: Phoenix II: Efficacy/Safety Study to Explore a New Revised Topical Formulation in Atopic Dermatitis (clinicaltrials.gov) - Nov 14, 2013
P=N/A, N=55, Recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment closed: GenTAC: National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions (clinicaltrials.gov) - Nov 13, 2013
P=N/A, N=3800, Active, not recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- pioglitazone / Generic mfg.
Trial withdrawal: Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients (clinicaltrials.gov) - Nov 7, 2013
P=N/A, N=0, Withdrawn, Sponsor: University of Rochester
Recruiting --> Active, not recruiting Not yet recruiting --> Withdrawn
- pioglitazone / Generic mfg.
Trial initiation date: Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients (clinicaltrials.gov) - Nov 7, 2013
P=N/A, N=0, Withdrawn, Sponsor: University of Rochester
Not yet recruiting --> Withdrawn Initiation date: Oct 2012 --> Mar 2013
- pioglitazone / Generic mfg.
Enrollment change: Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients (clinicaltrials.gov) - Nov 7, 2013
P=N/A, N=0, Withdrawn, Sponsor: University of Rochester
Initiation date: Oct 2012 --> Mar 2013 N=38 --> 0
- | Furestem-AD (hUCB-MSCs) / Kangstem Biotech
Enrollment change: Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis (AD) (clinicaltrials.gov) - Nov 6, 2013
P1/2, N=36, Recruiting, Sponsor: Kang Stem Biotech Co., Ltd.
N=38 --> 0 N=30 --> 36
- | Furestem-AD (hUCB-MSCs) / Kangstem Biotech
Enrollment open: Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis (AD) (clinicaltrials.gov) - Nov 6, 2013
P1/2, N=36, Recruiting, Sponsor: Kang Stem Biotech Co., Ltd.
N=30 --> 36 Not yet recruiting --> Recruiting
- Kineret (anakinra) / SOBI
Enrollment open: Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever (clinicaltrials.gov) - Nov 2, 2013
P3, N=50, Recruiting, Sponsor: Sheba Medical Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | ligelizumab (QGE 031) / Novartis
Trial completion: A Study Evaluating the Safety and Efficacy of QGE031 in Atopic Dermatitis Patients (clinicaltrials.gov) - Oct 20, 2013
P2, N=22, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Completed
- Enrollment change: A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing (clinicaltrials.gov) - Oct 3, 2013
P3, N=1, Terminated, Sponsor: Shire Regenerative Medicine, Inc.
Recruiting --> Completed N=21 --> 1
- REGN846 / Regeneron
Trial termination: Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic Dermatitis (clinicaltrials.gov) - Sep 26, 2013
P1/2, N=19, Terminated, Sponsor: Regeneron Pharmaceuticals
N=21 --> 1 Completed --> Terminated
- ||||| betamethasone/dexchlorpheniramine maleate / Generic mfg., prednisolone / Generic mfg.
Trial initiation date: Comparison of Desloratadine Associated With Prednisolone Oral Solution Versus Dexchlorpheniramine Associated With Betamethasone for Cutaneous Rash Treatment (clinicaltrials.gov) - Sep 23, 2013
P3, N=140, Not yet recruiting, Sponsor: EMS
Completed --> Terminated Initiation date: Jun 2013 --> Oct 2013
- ||||| Stelara (ustekinumab) / J&J
New P2 trial: A Study of Ustekinumab (STELARA (clinicaltrials.gov) - Sep 16, 2013
P2, N=72, Recruiting, Sponsor: Janssen Pharmaceutical K.K.
- | Trial completion: Feasibility Study: Higher Density Ulthera (clinicaltrials.gov) - Sep 8, 2013
P=N/A, N=21, Completed, Sponsor: Ulthera, Inc
Initiation date: Jun 2013 --> Oct 2013 Active, not recruiting --> Completed
- | Furestem-AD (hUCB-MSCs) / Kangstem Biotech
New P1/2 trial: Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis (AD) (clinicaltrials.gov) - Aug 21, 2013
P1/2, N=36, Recruiting, Sponsor: Kang Stem Biotech Co., Ltd.
- | Trial completion: Management of Pruritus With Xyzal in Atopic Dermatitis (clinicaltrials.gov) - Aug 13, 2013
P4, N=40, Completed, Sponsor: Derm Research, PLLC
Active, not recruiting --> Completed Active, not recruiting --> Completed